Answers are grounded in this paper and cite their sources.
OBJECTIVE: To examine differences in the incidence and spectrum of diseases, as well as duration of inpatient stay, between HIV-seronegative and HIV-seropositive narcotic drug, users (NDU). DESIGN: Retrospective analysis of 9 years of experience. Data collection by chart review using preset criteria for diagnoses. Estimation of hospital admission densities by assuming a dynamic but stable population of 2000 NDU (with a mean HIV-seroprevalence of 25%) throughout the study period. PATIENTS: Comprising 314 HIV-seronegative NDU. 217 HIV-seropositive NDU, and 10 NDU with admissions registered in either group (from a total of 1011 admissions). RESULTS: The overall admission incidence density was 35 and 120 per 1000 person-years among HIV-seronegative NDU and HIV-seropositive NDU, respectively [risk ratio (RR) 3.5, 95% confidence interval (CI) 3.2-3.7]. Compared with seronegative NDU, HIV-seropositive NDU were more frequently admitted for various non-opportunistic infections (RR 7.2, 95% CI 6.1-8.4), including pneumonia (RR 10.9, 95% CI 7.6-16.6), tuberculosis (RR 30.0, 95% CI 3.6-233.8), soft-tissue infections (RR 3.5, 95% CI 1.7-7.2), osteoarticular infections (RR 6.0, 95% CI 1.5-23.9), endocarditis (RR 5.3, 95% CI 1.5-17.9), and various other infections (RR 5.8, 95% CI 3.2-10.5). HIV-seropositive NDU were also more frequently admitted for non-infectious medical complications (RR 2.3, 95% CI 1.8-3.0). Seronegative NDU had a shorter median inpatient stay (2 versus 9 days, P < 0.00001). HIV infection accounted for an estimated excess burden of at least 2700 inpatient care days in 9 years among the 500 local HIV-seropositive NDU. CONCLUSIONS: Among NDU, HIV infection adds considerable excess burden in terms of severe complications needing inpatient care.
No takes yet. Share an insight, caveat, or question.
Scheidegger et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: